News
DSNKY
22.21
-2.33%
-0.53
Weekly Report: what happened at DSNKY last week (1124-1128)?
Weekly Report · 6d ago
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3
Seeking Alpha · 11/27 12:20
Weekly Report: what happened at DSNKY last week (1117-1121)?
Weekly Report · 11/24 09:22
Weekly Report: what happened at DSNKY last week (1110-1114)?
Weekly Report · 11/17 09:22
Daiichi Sankyo partnering with General Proximity on oncology targets
Seeking Alpha · 11/12 15:40
Weekly Report: what happened at DSNKY last week (1103-1107)?
Weekly Report · 11/10 09:21
Weekly Report: what happened at DSNKY last week (1027-1031)?
Weekly Report · 11/03 09:21
Daiichi Sankyo GAAP EPS of ¥70.52, revenue of ¥975.35B; updates FY outlook
Seeking Alpha · 10/31 08:54
Weekly Report: what happened at DSNKY last week (1020-1024)?
Weekly Report · 10/27 09:23
Weekly Report: what happened at DSNKY last week (1013-1017)?
Weekly Report · 10/20 09:22
Reported Sunday, AstraZeneca And Daiichi Sankyo's DATROWAY Extends Overall Survival By 5 Months And Reduces Progression Risk By 43% In Metastatic Triple-Negative Breast Cancer
Benzinga · 10/20 07:36
Reported Sunday, Daiichi Sankyo And Merck's Raludotatug Deruxtecan Shows 50.5% Objective Response Rate In Recurrent Platinum-Resistant Ovarian, Primary Peritoneal Or Fallopian Tube Cancer
Benzinga · 10/20 07:20
Astra, Daiichi post late-stage data to show Enhertu’s potential in early breast cancer
Seeking Alpha · 10/18 18:18
Weekly Report: what happened at DSNKY last week (1006-1010)?
Weekly Report · 10/13 09:22
Weekly Report: what happened at DSNKY last week (0929-1003)?
Weekly Report · 10/06 09:21
AstraZeneca And Daiichi Sankyo Report Phase 3 Results Showing Datroway's Superiority To Chemotherapy In First-Line Metastatic Triple Negative Breast Cancer
Benzinga · 10/06 07:24
AstraZeneca, Daiichi win FDA review for Enhertu label expansion
Seeking Alpha · 10/01 11:53
Weekly Report: what happened at DSNKY last week (0922-0926)?
Weekly Report · 09/29 09:22
Daiichi Sankyo And AstraZeneca's ENHERTU Demonstrates Statistically Significant Improvement In Invasive Disease-Free Survival Versus T-DM1 In DESTINY-Breast05 Phase 3 Trial
Benzinga · 09/29 06:59
Trump’s 100% drug tariffs send pharma stocks lower
Seeking Alpha · 09/26 08:59
More
Webull provides a variety of real-time DSNKY stock news. You can receive the latest news about Daiichi Sankyo through multiple platforms. This information may help you make smarter investment decisions.
About DSNKY
Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.